Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development of innovative cancer treatments. Its primary product candidate, IPI-549, is an orally administered immuno-oncology drug currently in Phase 2 clinical trials for metastatic triple negative breast cancer and urothelial cancer, as well as Phase 1/1b trials for solid tumors. The company generates revenue through strategic alliances and collaboration agreements with other pharmaceutical companies, such as Intellikine, Verastem, PellePharm, Arcus Biosciences, F. Hoffmann-La Roche, and Bristol Myers Squibb, to research, develop, and commercialize various pharmaceutical products targeting specific cancer-related enzymes and pathways.

Products

• IPI-549 (immuno-oncology product candidate)